UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022919
Receipt number R000026408
Scientific Title Association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate: a retrospective observational study
Date of disclosure of the study information 2016/07/01
Last modified on 2016/06/27 22:30:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate: a retrospective observational study

Acronym

Association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate: a retrospective observational study

Scientific Title

Association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate: a retrospective observational study

Scientific Title:Acronym

Association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate: a retrospective observational study

Region

Japan


Condition

Condition

Critically ill patients who required continuous renal replacement therapy

Classification by specialty

Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To observe the association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy with nafamostat mesilate.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

the incidence of bleeding complications

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Adult critically ill patients who required continuous renal replacement therapy in our intensive care unit from January 2011 to December 2013.

Key exclusion criteria

Patients who required additional extracorporeal intervention including extracorporeal membrane oxygenation or intra-aortic balloon pumping.
Patients who were administered other anticoagulants including unfractionated heparin and gabexate mesilate.

Target sample size

122


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Moritoki Egi

Organization

Kobe University Hospital

Division name

Anesthesiology

Zip code


Address

7-5-2, Chuo-ku, Kobe, Hyogo

TEL

0783826172

Email

moriori@tg8.so-net.ne.jp


Public contact

Name of contact person

1st name
Middle name
Last name Shohei Makino

Organization

Kobe University Hospital

Division name

Anesthesiology

Zip code


Address

7-5-2, Chuo-ku, Kobe, Hyogo

TEL

0783826172

Homepage URL


Email

timasuke555@yahoo.co.jp


Sponsor or person

Institute

Kobe University Hospital

Institute

Department

Personal name



Funding Source

Organization

nil

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 06 Month 01 Day

Date of IRB


Anticipated trial start date

2015 Year 08 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

patients demographics
the incidence of bleeding complications
filter life


Management information

Registered date

2016 Year 06 Month 27 Day

Last modified on

2016 Year 06 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026408


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name